Dr. Freedman is the founding President of the Global Biological Standards Institute (GBSI). He has held leadership positions in basic biomedical research, drug discovery, and science policy in both the private and non-profit sectors, as well as in academia.Prior to starting GBSI, Dr. Freedman served as Vice Dean for Research and Professor of Biochemistry and Molecular Biology at Jefferson Medical College, Thomas Jefferson University. Dr. Freedman also led discovery research efforts in the pharmaceutical industry as a Vice President at Wyeth and Executive Director at Merck. Before moving to industry, Dr. Freedman was a Member and Professor of Cell Biology & Genetics at Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College. There, Dr. Freedman and his lab made several highly impactful discoveries in the area of nuclear hormone receptor structure and function.Dr. Freedman has received numerous competitively funded grants, and has been the recipient of several research honors, including the Boyer Award for Biomedical Research, and a MERIT award from the National Institutes of Health. He was also the 2002 recipient of the Ernst Oppenheimer Award from The Endocrine Society. Dr. Freedman has published extensively and served on numerous scientific review panels and editorial boards. He was an editor of the journal Molecular and Cellular Biology for ten years. In addition, Dr. Freedman has served on the Board of Directors of the American Type Culture Collection (ATCC).Dr. Freedman earned a B.A. degree in Biology from Kalamazoo College, and a Ph.D. in Molecular Genetics from the University of Rochester. He completed his post-doctoral fellowship in the laboratory of Dr. Keith Yamamoto at the University of California, San Francisco.
Vivian Siegel is the Director of Education and Training at GBSI as well as an adjunct research professor of medicine at Vanderbilt University and a visiting instructor at MIT.
Formally trained as a scientist, Dr. Siegel is an accomplished educator and communicator of science with deep expertise in scientific publishing and open-access journals. She has served as editor of leading scientific journals, including Cell and PLOS Biology, and she founded and directed the Center for Science Communication (CSC) at Vanderbilt University.Prior to joining GBSI, Dr. Siegel served the Broad Institute of MIT and Harvard as its Director of Scientific Education and Public Communication and later as its Director of Education and Outreach. Dr. Siegel was formerly the executive director of the Public Library of Science, the chief editor of Cell, Developmental Cell, and Molecular Cell, the founding editor-in-chief of Disease Models & Mechanisms and the executive editor of the Journal of the American Society of Nephrology.Dr. Siegel received her A.B. in biochemistry and mathematics from Bowdoin College and her Ph.D. in genetics from University of California San Francisco.
Michael Byrne is the Director of Strategic Program Development, overseeing GBSI’s program and partnership development as well as operations. Prior to this, Mr. Byrne was GBSI’s first Director of Operations.Prior to joining GBSI, Mr. Byrne was the first Head of Operations for the Center for Responsible Enterprise and Trade (CREATe.org), a Washington, DC-based non-profit founded in 2011 to work with global multinational corporations to better engage with their vast supply chains in the high-risk markets on issues of intellectual property protection and anti-corruption.Previously, Mr. Byrne was Director of Operations for the Institute of International Banking Law & Practice where he led operations, oversaw the development of the Certified Standby & Guarantee Practitioner Global Certification program, and coordinated multiple global conferences and publications.Mr. Byrne is a graduate of The Florida State University.
Carol Miller is the Senior Communications Advisor for GBSI. She focuses on building long term relationships with mainstream and scientific media focused on issues central to the advancement and quality of biomedical research and improving global health, and advising on communications as the organization grows.She has worked for 25 years in more than 20 countries as a communications strategist and practitioner in global health, international development and disaster response.Since 2008, Ms. Miller has consulted with NGOs, and organizations dedicated to global health, disease control, disaster management, improved governance, and the performing arts. She co-authored the National Pandemic Communications Response Plan for Saint Lucia, developed international health and pharmaceutical communications plans, and managed media outreach.Prior to consulting, she was a communicator for the American Red Cross, where she last led international communications. She managed Red Cross U.S. advocacy and communications capacity building for the Measles Initiative in Africa and Asia; and public affairs on site and from headquarters for more than 100 disaster responses— including the 2004 Southeast Asia tsunami, 1999 Balkans crisis, and in New York following 9/11.Ms. Miller has a B.A. in Communications with honors from Washington State University.
Lauren Shihar is the Business Operations Coordinator where she supports areas of finance, membership and events.
Prior to GBSI, Ms. Shihar was at Michael J. Hennessy, Inc., a full-service healthcare communications company where she executed OncLive’s Giants of Cancer Care® program at Chemotherapy Foundation Symposium and The American Society of Clinical Oncology (ASCO) annual meetings in 2015 & 2016. Additionally, she managed programs across various franchises and played an active role in shaping the culture of the organization as they expanded and relocated in 2017.
Ms. Shihar earned her B.S. in Life Sciences from The Eberly College of Science at The Pennsylvania State University.
Dr. Jithesh Veetil, PhD joined GBSI in 2017 as Scientific Program Manager to lead the development and implementation of multiple programs on science policy, communications, and advocacy, including those related to cell line authentication, antibody validation, and reproducibility. Dr. Veetil works with various external stakeholders to advance partnership, fundraising, and other collaborative opportunities. Dr. Veetil has extensive experience in designing and development of programs towards modernizing scientific workforce and practices by building academic-industrial-nonprofit collaboration through his work at National Institutes of Health (NIH) campus as the lead scientist and program manager for the Foundation for Advanced Education in the Sciences (FAES).
Dr. Veetil received PhD in Biomedical Engineering at University of Arkansas, Fayetteville, AR where he developed innovative implantable continuous glucose monitoring sensors and diabetes drug discovery tools in collaboration with Bayer Healthcare. He completed postdoctoral fellowship in biophotonics at NIH, focusing on assays and methods development for studying abnormal protein interactions, mainly in cardiovascular and neuronal disorders. He received training on Health Policy & Biomedical Business Development through the FAES Graduate School at NIH, and also completed intensive training program on Biomedical Device Development through Harvard University Catalyst Postgraduate Continuing Education Program. Dr. Veetil holds a Masters in Biotechnology and Bachelors in Food Technology. Dr. Veetil has published numerous peer-reviewed manuscripts, reviews and book chapters.
Dr. Veetil at NIH campus co-chaired the Visiting Fellows Committee to develop a wide range of seminars and workshops towards scientific and professional development of 4,000 plus research trainees at NIH and the scientific community in and around DC area. He was the founding head of the department of Biotechnology at DG Vaishnav College at University of Madras, India. Dr. Veetil was also the Operations Manager for Preludesys Inc., and worked with international clientele from medical, IT, insurance and paralegal organizations on medical data management.